

## Trade Press Release

# IBSA UK&I Celebrates its Historic Debut at ACE 2026, Winning the Prestigious “Injectable Product of the Year” Award for Prophilos<sup>®</sup> Structura

*London, 26th March 2026* – With great pride, IBSA UK & Ireland participated for the first time under the name “IBSA” in the Aesthetics Conference & Exhibition (ACE) 2026. The event provided an important opportunity to highlight its scientific leadership, the innovation of its portfolio, and its ongoing commitment to raising standards in the field of regenerative aesthetics, culminating in a triumphant evening at the Aesthetics Awards.

### **A New Era for Full-Face Treatment**

At ACE, IBSA hosted a symposium titled: ***Beyond Prophilos<sup>®</sup>: IBSA’s Full-Face Approach to Ageing***. The event offered professionals an overview of the growing field of aesthetics focused on adipose tissue, with a particular focus on **Prophilos<sup>®</sup> Structura**, the first injectable product developed specifically for adipose tissue restoration.

Delivered by leading international experts, the session covered:

- Adipose restoration providing a non-surgical solution for deeper facial support
- How to tailor treatment plans to individual patient anatomy
- Technique considerations that optimise safety, outcomes, and integration
- A multimodal approach using IBSA’s complementary portfolio: **Prophilos<sup>®</sup> Structura**, **Viscoderm<sup>®</sup> Hydrobooster**, and **Aliaxin<sup>®</sup> SR & FL**.

**Two live demonstrations** offered delegates real-time insight into IBSA’s anatomy-led methodology, reinforcing the company’s dedication to scientific rigour, patient safety, and authentic aesthetic outcomes.

Official training is now available directly through IBSA, and via respected partner academies: IICM, Harley Academy, and Healthxchange Academy, expanding access and offering multiple pathways into IBSA’s educational ecosystem.

## **Profilo® Structura Wins “Injectable Product of the Year” Award**

Profilo® Structura was awarded ***Injectable Product of the Year***, reflecting its category defining impact on structural, adipose tissue restoration and its advancement of aesthetic treatment possibilities.

The award underscores IBSA's leadership in innovation, as well as the value of NAHYCO® technology, creating hybrid cooperative complexes of hyaluronic acid that improve the environment within all layers of the skin so that multiple cells, including fibroblasts that stimulate collagen and elastin, and adipose cells that restore fat pads, are able to thrive, and counteract the signs of ageing, leading to a lifting effect, improved hydration and skin firmness.

*“We are honoured to receive the ‘Injectable Product of the Year’ award for Profilo® Structura.”* says Alex Stuart, Head of Derma UK & Ireland. *“This recognition signals a new chapter for adipose focused aesthetics and reinforces IBSA’s mission to continue empowering practitioners with the science, training, and technologies that enable safer, more natural, and truly patient-centred outcomes.”*

Shannon Kilgariff, Event Director and Publisher of Aesthetics, said: *“We are absolutely delighted to recognise IBSA UK&I as WINNER of Injectable Product of the Year at The Aesthetics Awards, we are proud to stand at the forefront of excellence, with our 100 industry-leading judges deciding which individuals, clinics, and companies are shining brightest in the UK medical aesthetics specialty. Profilo® Structura is more than deserving as the Winner for their valuable contributions to the sector.”*

## **Engaging the Aesthetic Community**

Throughout the conference, the IBSA UK&I team met with practitioners from across the UK and Ireland, strengthening new relationships and offering:

- Reassurance of authentic product supply, showcasing the official IBSA UK & Ireland hologram on all Profilo® boxes - available exclusively through IBSA and trusted pharmacy partners
- Guidance on IBSA's evolving clinical education pathway
- Insight into the company's multimodal approach to regenerative treatment

These interactions form part of IBSA's “listening first” philosophy, ensuring practitioner needs continue to shape the company's UK&I strategy.

## **Celebrating Excellence: Sponsoring “Best New Clinic UK & Ireland”**

As an official sponsor of the Aesthetics Awards 2026, IBSA UK&I proudly presented the award for **Best New Clinic UK & Ireland** to Hart Medical, praised for their authentic, ethical, education-first positioning, highlighting its strong patient focus and aftercare processes. IBSA will continue to champion those elevating professional standards across the aesthetic sector.

**For further information and to register interest in official IBSA training:**

[training.derma.uk@ibsagroup.com](mailto:training.derma.uk@ibsagroup.com)

IBSA UK&I

Alex Stuart, 01923 233 466, [derma.uk@ibsagroup.com](mailto:derma.uk@ibsagroup.com)

[www.ibsaderma.co.uk](http://www.ibsaderma.co.uk)

**About IBSA**

IBSA (*Institut Biochimique SA*) is a Swiss pharmaceutical multinational with 20 subsidiaries across Europe, China, and the United States. Its products are available in over 90 countries, and its R&D activities focus on 10 therapeutic areas. In 2025, IBSA celebrated the 40<sup>th</sup> anniversary of its acquisition by current President and CEO, Arturo Licenziati, who has transformed the company into a multinational corporation employing over 2,500 personnel worldwide. IBSA's growth and development can be attributed to its ability to innovate by refining well-known molecules, as well as to its commitment to looking to the future responsibly and transparently, thanks to the dedication and dynamism of its people.